Ahead of the event, the Ireland-based drugmaker has crept up to a trendline that could have historically bearish implications. More specifically, Endo stock recently ran up to its 60-day moving average after spending a considerable amount of time below the trendline. At last check, ENDP was down 2.4% to trade at $8.07, meaning a drop of a similar magnitude would put the stock around $7.15, and back below its year-to-date breakeven level by next month. In the options pits, calls have been almost exclusively targeted, despite limited absolute volume. Visit SchaeffersResearch.com to discover how you can use stock options to complement your investing portfolio.

Source: Forbes May 07, 2019 15:45 UTC